Open Label Pilot Study of 2% Tofacitinib for the Treatment of Refractory Vitiligo.

Open Label Pilot Study of 2% Tofacitinib for the Treatment of Refractory Vitiligo. Br J Dermatol. 2019 Oct 12;: Authors: Mobasher P, Guerra R, Jiayang Li S, Frangos J, Ganesan AK, Huang V Abstract Treatment options for vitiligo are limited and many cases remain refractory to first and second line treatments. Interferon-gamma signaling mediated by Janus kinase (JAK) has been implicated in the pathogenesis of vitiligo.1 Systemic administration of tofacitinib, a potent JAK1/3 inhibitor, has been effective in treating vitiligo in case reports,2 however, it is associated with infections, malignancies, cytopenias, gastrointestinal perforations, and hyperlipidemia in some patients with rheumatoid arthritis. PMID: 31605536 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research

Related Links:

Immunologic adverse reactions of β-blockers and the skin. Exp Ther Med. 2019 Aug;18(2):955-959 Authors: Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC Abstract β-Blockers are a widely utilised class of medication. They have been in use for a variety of systemic disorders including hypertension, heart failure and intention tremors. Their use in dermatology has garnered growing interest with the discovery of their therapeutic effects in the treatment of haemangiomas, their potential positive effects in wound healing, Kaposi sarcoma, melanoma and pyogenic granuloma, and, more recently,...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
AbstractSelective immunoglobulin A deficiency (SIgAD) is the most common primary immunodeficiency, defined as an isolated deficiency of IgA (less than 0.07  g/L). Although the majority of people born with IgA deficiency lead normal lives without significant pathology, there is nonetheless a significant association of IgA deficiency with mucosal infection, increased risks of atopic disease, and a higher prevalence of autoimmune disease. To explain thes e phenomena, we have performed an extensive literature review to define the geoepidemiology of IgA deficiency and particularly the relative risks for developing systemic...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Publication date: Available online 3 May 2019Source: Autoimmunity ReviewsAuthor(s): Haroon Khan, Antoni Sureda, Tarun Belwal, Sümeyra Çetinkaya, İpek Süntar, Silvia Tejada, Hari Prasad Devkota, Hammad Ullah, Michael AschnerAbstractIn addition to protecting body from infections and diseases, the immune system produces auto-antibodies that can cause complex autoimmune disorders, such as Type I diabetes, primary biliary cirrhosis, rheumatoid arthritis, and multiple sclerosis, to name a few. In such cases, the immune system fails to recognize between foreign agents and its own body cells. Different factors, s...
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
To the Editor: Current treatments for vitiligo are limited in efficacy, often producing suboptimal results. Recent studies have established that CD8+  T-cell and interferon γ signaling, mediated by the Janus kinase (JAK)–signal transducer and activator of transcription pathway, contribute to the pathogenesis of vitiligo.1 JAK inhibitors block this pathway and are currently Food and Drug Administration approved for autoimmune diseases, includi ng psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and myeloproliferative disorders.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Tags: Research letter Source Type: research
Qiancheng Deng1, Yangyang Luo1,2, Christopher Chang3, Haijing Wu1, Yan Ding4* and Rong Xiao1* 1Hunan Key Laboratory of Medical Epigenetics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, China 2Department of Dermatology, Hunan Children's Hospital, Changsha, China 3Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Davis, CA, United States 4Department of Dermatology, Hainan Provincial Dermatology Disease Hospital, Haikou, China Autoimmune diseases are usually complex and multifactorial, characterized by aberrant produc...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
We present a series of 6 women with a mean age of 64.2 years and a mean latency of 9.5 years between radiotherapy for breast cancer and onset of morphea. Four of the patients had a history of autoimmune disease: rheumatoid arthritis, Sjögren syndrome, vitiligo, and Crohn disease. No specific risk factors for postirradiation morphea have been identified to date, although it would appear that a history of autoimmune disease could be associated with an increased risk of morphea in patients treated with radiation therapy.ResumenLa morfea postradioterapia es una entidad poco frecuente descrita mayoritariamente en mujeres c...
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Source Type: research
Publication date: Available online 11 January 2019Source: Autoimmunity ReviewsAuthor(s): Silvia Martina Ferrari, Poupak Fallahi, Ilaria Ruffilli, Giusy Elia, Francesca Ragusa, Salvatore Benvenga, Alessandro AntonelliAbstractGraves' disease (GD) and autoimmune thyroiditis (AT) are the two main clinical presentations of AITD, and their clinical hallmarks are thyrotoxicosis and hypothyroidism, respectively. GD, and AT, can be associated with other organ specific, or systemic autoimmune diseases in the same patient. However discordant results have been reported in the literature about the possible associations. Here, we review...
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
Authors: Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L Abstract The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such as psoriasis, alopecia areata, atopic dermatitis and vitilig...
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Abstract A 59-year-old Native American female presented with a 4-day history of malaise, abdominal pain, nausea, jaundice, and a "sunburn-like rash" on the upper chest and back despite lack of recent sun exposure (Figure 1). Medical history was significant for a twenty-year history of universal vitiligo and a five-year history of rheumatoid arthritis (RA) treated with methotrexate (MTX), adalimumab, prednisone, and naproxen sodium. Cutaneous examination revealed hemorrhagic crusting of upper and lower lips (Figure 2), scleral icterus, diffuse jaundice of the skin, and well-demarcated erythematous patches...
Source: Skinmed - Category: Dermatology Authors: Tags: Skinmed Source Type: research
We present a series of 6 women with a mean age of 64.2 years and a mean latency of 9.5 years between radiotherapy for breast cancer and onset of morphea. Four of the patients had a history of autoimmune disease: rheumatoid arthritis, Sjögren syndrome, vitiligo, and Crohn disease. No specific risk factors for postirradiation morphea have been identified to date, although it would appear that a history of autoimmune disease could be associated with an increased risk of morphea in patients treated with radiation therapy. PMID: 30389122 [PubMed - as supplied by publisher]
Source: Actas Dermo-Sifiliograficas - Category: Dermatology Authors: Tags: Actas Dermosifiliogr Source Type: research
More News: Arthritis | Cancer & Oncology | Dermatology | Gastroenterology | Rheumatoid Arthritis | Rheumatology | Skin | Study | UK Health | Vitiligo